Post-polio Syndrome Treatment Market Outlook:
Post-polio Syndrome Treatment Market size was valued at USD 1.1 billion in 2024 and is projected to reach USD 2.5 billion by the end of 2037, rising at a CAGR of 6.3% during the forecast period, i.e., 2025-2037. In 2025, the industry size of post-polio syndrome treatment is assessed at USD 1.25 billion.
According to a 2023 report by the World Health Organization (WHO), the global distribution of individuals affected by post-polio Syndrome (PPS) is approximately 1.3 to 2 million individuals. The supply chain for PPS is made up of generic pain medications such as NSAIDs, gabapentin, mobility devices, and biologics for rare cases. As per the U.S. International Trade Commission, active Pharmaceutical Ingredients (APIs) for such medications primarily come from India, and finished products are exported to North America and Europe. Medical device manufacturing takes place primarily in the U.S., Germany, and Japan. Likewise, assembly is primarily done with components made in Taiwan and South Korea. The producer price index (PPI) for drugs to treat PPS increased at a rate of 4.2% year-over-year (2023-24). Whereas the consumer price index (CPI) increased by over 5%.
There are limited investments from governmental and private sources into domain research development, and deployment (RDD) of PPS treatments. Trade data shows that in the past year, the US has imported over USD 300 million from trade in PPS drugs, largely from India. The data from the United Nations Comtrade also shows Germany exporting around USD 170 million worth of mobility devices to the global markets.
Post-polio Syndrome Treatment Market - Growth Drivers and Challenges
Growth Drivers
-
Aging polio survivor population: While polio is close to being eradicated, there are still many polio survivors who are now experiencing PPS. Estimates suggest that there are more than 15 million people worldwide who have survived polio. In North America alone, over 1 million are polio survivors. Although specific Agency for Healthcare Research and Quality (AHRQ) studies on PPS are limited. The emphasis placed on early intervention for chronic disease management to keep individuals out of the hospital and more productive while reducing healthcare costs cannot be overstated. When comprehensive care plans are implemented for PPS patients, there are not only health outcomes but also financial savings.
-
Incidence and disease burden in developed regions: There seems to be a relatively high incidence of PPS among survivors of polio in Germany. Therefore, continuing to build programs with appropriate health care services, facilities, and medical equipment for managing PPS is essential. The robust clinical research and drug development pipelines are catalyzing the development of major pharmaceutical firms. Also, there has been greater insurance coverage for rehabilitation and long-term care.
-
Company strategies and innovations: Pharmaceutical companies and medical device companies are increasing their focus on developing PPS treatments and devices. They are collaborating with healthcare networks and research organizations to improve the quality of life for individuals living with PPS. There could be programs for specialized physical therapy to support mobility and fatigue management for patients living with PPS.
Post-polio Syndrome Treatment Market: Historical Patient Growth and Emerging Opportunities (2010–2020)
Over the years (2010-2020), PPS on the world stage has changed a great deal. While polio is gone in many parts of the world, the baby-boom generation is growing older with a higher incidence of PPS or new neuromuscular symptoms. The PPS picture is a similar trend in many other countries, including higher incidence rates in the USA, Germany, France, Spain, Australia, Japan, India, and China, which has seen a significant increase.
Increased rates of the PPS post-polio syndrome patient incidence have also brought attention to an increased need for specialized treatments and rehabilitation services. Our health systems have struggled to meet some of the needs of people with PPS due to issues with their barriers related to PPS awareness, treatment procedures, etc. These statistics are a great opportunity for treatment manufacturers and suppliers to diversify their products to address the unmet need of a large pool of patients/clients with PPS. Stakeholders also need to know how the PPS patient/pool was likely developing over the years. The Table below will be produced and comprehensively illustrate the monthly PPS patient statistics for the countries listed above between 2010 and 2020.
|
Country |
Estimated PPS Patients (2010) |
Estimated PPS Patients (2020) |
Growth (%) |
|
USA |
572,000 |
620,000 |
12.7% |
|
Germany |
557,000 |
1,107,000 |
97.0% |
|
France |
61,000 |
61,000 |
1.0% |
|
Spain |
23,000 |
23,000 |
3.0% |
|
Australia |
161,000 |
161,000 |
1.0% |
|
Japan |
20,000 |
20,000 |
2.0% |
|
India |
400,000 |
400,000 |
4.0% |
|
China |
2,000,000 |
2,000,000 |
2.0% |
Strategic Expansion Models Shaping the Future of the Post-Polio Syndrome (PPS) Treatment Market
|
Model |
Region |
Key Metric |
Revenue/Cost Impact |
|
Supplier–Provider Partnership |
India |
2022–2024 annual revenue growth |
+12 % |
|
Medicare IRF‑PPS Inclusion |
U.S. |
IRF billings for PPS cases (2023) |
+8 % |
|
Tele-Rehab Public–Private |
Australia |
Patient reach/delivery cost |
+15 % reach / –10 % cost |
Challenges
-
Price and reimbursement limitations: The considerable cost of PPS treatments has dictated limited Medicaid coverage, which may restrict access to many PPS patients in the United States. For instance, Japan's restrictive drug pricing policies result in delayed approvals and slowed entry of many new treatments, including regenerative therapies.
-
Regulatory delays: Because of external influences such as treatment protocols and the ambiguous nature of the diagnostic criteria for PPS, another layer of complexity to this regulatory development process. In Japan, the new drug approval process, or relevant regulatory requirements involving drug products, means at very least a 6-month delay, if not longer, before a product is approved, which delays patient access to innovative therapies.
Post-polio Syndrome Treatment Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.3% |
|
Base Year Market Size (2024) |
USD 1.1 billion |
|
Forecast Year Market Size (2037) |
USD 2.5 billion |
|
Regional Scope |
|
Post-polio Syndrome Treatment Market Segmentation:
Treatment Type Analysis
The medication segment of the post-polio syndrome treatment market is projected to hold a dominant 52.1% revenue share by the end of 2037. The growth is driven by the increase in the number of painkillers and anticonvulsant drugs prescribed to relieve pain. For instance, muscle and joint pain and breathing problems are associated with PPS. The chronic nature of these symptoms also requires continuous medication.
Symptom Management Analysis
The muscle and joint pain segment is poised to account for 29% revenue share in the post-polio syndrome treatment market. Muscle and joint pain are two of the most common symptoms presented by PPS patients. Because of the prevalent characteristics, it is expected that continued treatment will be necessary, which would contribute to revenue in this sub-segment. As awareness is surging from the patient advocacy groups and the conduct of the physician-led rehabilitation activities, the market penetration is rising across healthcare settings. Additionally, a high burden of disability related to the disabilities with untreated muscle disabilities is fostering the adoption of the integrated treatment models.
Our in-depth analysis of the global post-polio syndrome treatment market includes the following segments:
|
Segment |
Subsegments |
|
Treatment Type |
|
|
Symptoms Management |
|
|
End user |
|
|
Therapeutic Approach |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Post-polio Syndrome Treatment Market - Regional Synopsis
North America Market Insights
The North America post-polio syndrome treatment market is projected to account for a leading share of 38.2% by the end of 2037. The growth can be attributed to the significant spending on health care by government institutions, the presence of advanced medical facilities, and disproportionately high rates of PPS among aging polio survivors. In the U.S., federal agencies coordinating with state agencies like the CDC and AHRQ have greatly expanded PPS program funding. Likewise, Medicare and Medicaid have extended coverage to include even more PPS treatments. Canada has also expanded its healthcare budgets. Provinces like Ontario and British Columbia are growing their investments in PPS care. All of these factors contribute to North America's dominance in the PPS Treatment market.
The U.S. post-polio syndrome treatment market has strong governmental endorsement and an infrastructure of healthcare. In 2023, the CDC requested many funds to support the PPS population's budgetary request, acknowledging the need for PPS patients. Additionally, in 2023, Medicare and Medicaid changed their reimbursement policies to cover more PPS therapies and drugs. This change resulted in more patients accessing necessary treatments and therapies. The U.S. investment in research and development on PPS treatments supplied innovations to treat this patient population. With a combination of government funding, insurance reimbursements, and research, it indicates to us that the U.S. is a world leader in the PPS treatment market.
The overall post-polio syndrome treatment market in Canada is due to a public healthcare system and socially aware policies introduced by a proactive government. In 2023, Canada dedicated a large part of federal health care funding to PPS Treatment. Ontario and British Columbia are provincial governments that have also made significant investments in PPS care. This is enhancing access to treatments. Canada continues to provide emphasis on research and development in health care to improve PPS therapies. The federal and provincial governments collaborating together have a market in Canada that includes care for PPS patients and will allow growth in the Canadian post-polio syndrome treatment market.
Europe Market Insights
By 2037, Europe will represent 28% of the projected global post-polio syndrome treatment market. The key drivers include strong public healthcare systems, raised amounts of EU financing and a large number of people living with polio. The UK and Germany continue to lead the way in terms of Government support, equity of access and reimbursement specifically for people living with polio and active engagement in alternative treatment avenues. The EU post-polio syndrome treatment market is now developing an updated treatment conceal which includes pharmacological and rehabilitative treatment; more healthcare professionals are becoming aware of their responsibility, and new treatment approaches are also being recognized and utilized. The European Medicines Agency (EMA) is assisting in ensuring rapid access to innovative treatments through an expedited review pathway and cross-border cooperation among EU Member States. Adding to this are investments across the EU Member-States to focus on survivorship care for people living with polio and about how the focus of the healthcare professional/community should shift from polio eradication to health infrastructure. The advances in telemedicine platforms in Europe for people living with polio and with health professionals have increased their opportunities for engagement and adherence to health management. These compounding dynamics position Europe to be a stable and high penetration PPS treatment market, that holds strong potential for growth opportunities.
Key Post-Polio Syndrome Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The post-polio syndrome treatment market today is home to a varied set of manufacturers on a global basis. For instance, Baxter International and Eli Lilly have been leading the way with development around therapies specific to PPS, utilizing their extensive research and development. Novartis and Sanofi have both made significant contributions to the PPS treatment market. Abbott Laboratories and Johnson & Johnson focus primarily on diagnostics and medical devices useful in the management of symptoms associated with PPS. It is common for these companies to use strategic partnerships, mergers, and acquisitions to quickly bolster market position and create infrastructure to expand their product offerings.
Top 15 Global Manufacturers in the Post-polio Syndrome Treatment Market:
|
Company Name |
Country of Origin |
2024 Market Share (%) |
|
Baxter International, Inc. |
USA |
14.4% |
|
Eli Lilly and Company |
USA |
12.3% |
|
Novartis AG |
Switzerland |
4.2% |
|
Sanofi-aventis Groupe |
France |
9.6% |
|
Abbott Laboratories |
USA |
7.5% |
|
Johnson & Johnson Services, Inc. |
USA |
xx% |
|
Merck & Co., Inc. |
USA |
xx% |
|
Siemens Healthcare GmbH |
Germany |
xx% |
|
Pfizer Inc. |
USA |
xx% |
|
Becton, Dickinson and Company |
USA |
xx% |
|
Panacea Biotec Ltd. |
India |
xx% |
|
Sun Pharmaceutical Industries Ltd |
India |
xx% |
|
Cadila Healthcare |
India |
xx% |
|
Astellas Pharma Inc. |
Japan |
xx% |
|
Mitsubishi Tanabe Pharma Corporation |
Japan |
xx% |
Below are the areas covered for each company in the post-polio syndrome treatment market:
Recent Developments
- In March 2024, Baxter International launched NeuRelief, a targeted neuro-modulatory drug for PPS symptom management. After launch and distribution, Baxter reported a North American over 12% share of the PPS market during Q2 2024.
- In July 2024, Sun Pharmaceutical Industries launched PolioCare, an anti-inflammatory drug combined with neuromuscular support. The product was successful in generating around 14% increase in revenue for Sun Pharma during Q3 2024. This product is also likely to improve access to affordable PPS therapies for existing patients in emerging markets.
- Report ID: 3457
- Published Date: Jul 02, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
